证券代码：300289 证券简称：利德曼 公告编号：2025-056 北京利德曼生化股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 2025 年第一次临时股东大会决议公告 特别提示： 2、会议召开方式：本次股东大会会议采取现场投票和网络投票 相结合的方式召开。 3、会议召开时间： （1）现场会议时间：2025 年 11 月 21 日（星期五）下午 14:00 时。 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络 投票的时间为：2025年11月21日9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网系统投票具体时间为：2025 年 11 月 21 日 9:15-15:00。 4、现场会议召开地点：北京市北京经济技术开发区兴海路 5 号 公司二层会议室。 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、北京利德曼生化股份有限公司（以下简称"公司"或"本公司"） 2025 年第一次临时股东大会通知于 2025 年 10 月 29 日 ...

Core Viewpoint - Lidman is undergoing a transformation through a high-premium acquisition of 70% of Xiansheng Xiangrui's shares for 1.733 billion yuan, despite facing performance pressures and a significant cash shortfall [3][4]. Group 1: Acquisition Details - Lidman plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, representing a 162% premium over the company's book value [3][4]. - The acquisition will result in approximately 1.019 billion yuan of goodwill on Lidman's balance sheet, raising concerns about potential impairment if Xiansheng Xiangrui's actual performance falls short of expectations [4][6]. - Xiansheng Xiangrui's estimated total equity value is 2.674 billion yuan, with a significant increase from its book value of 1.02 billion yuan [4]. Group 2: Financial Performance of Xiansheng Xiangrui - Xiansheng Xiangrui's revenue and net profit have shown a declining trend, with projected revenues of 653 million yuan in 2023 and 582 million yuan in 2024, alongside net profits of 210 million yuan and 180 million yuan respectively [5]. - The company's core product, TB-PPD, has a high revenue dependency, accounting for 95.95% of revenue in 2023, which poses risks if sales do not meet expectations [6][7]. Group 3: Lidman's Financial Challenges - Lidman reported a significant cash shortfall, with only 618 million yuan available against the acquisition cost of 1.733 billion yuan [7][8]. - The company is expected to pay 70% of the acquisition price (1.213 billion yuan) shortly after the agreement, which is nearly equivalent to its total cash reserves [7]. - Lidman has faced declining revenues and profits, with a projected revenue drop of 19.79% in 2024 and a net loss of 75.1 million yuan [8].

一、召开会议的基本情况 1、股东大会届次：2025年第一次临时股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：公司第六届董事会第六次会议审议通过 《关于召开2025年第一次临时股东大会的议案》，本次会议的召开符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。 证券代码：300289 证券简称：利德曼 公告编号：2025-055 北京利德曼生化股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要提示： 北京利德曼生化股份有限公司（以下简称"公司"）于2025年10月29日在巨 潮资讯网刊登了《关于召开2025年第一次临时股东大会的通知》，为进一步保 护投资者的合法权益，方便公司股东行使股东大会表决权，现将股东大会的有 关事项提示如下： 4、会议时间： （1）现场会议时间：2025年11月21日14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为2025年11月21日9:15-9:25，9:30-11:30，13:00-15:00；通过 ...

证券之星消息，11月18日医疗器械板块较上一交易日下跌0.51%，利德曼领跌。当日上证指数报收于 3939.81，下跌0.81%。深证成指报收于13080.49，下跌0.92%。医疗器械板块个股涨跌见下表： 从资金流向上来看，当日医疗器械板块主力资金净流出15.93亿元，游资资金净流入4.0亿元，散户资金净 流入11.93亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301367 | 瑞迈特 | 87.58 | 3.50% | 1.91万 | | 1.68亿 | | 301097 | 天益医疗 | 61.53 | 3.05% | 1.92万 | | 1.15亿 | | 300049 | 福瑞股份 | 69.80 | 2.42% | 6.98万 | | 4.86 乙 | | 688410 | 山外山 | 16.55 | 1.85% | 6.92万 | | 1.14亿 | | 688026 | 洁特生物 | 18.77 | 1.79% | 3 ...

长江商报消息 ●长江商报记者 江楚雅 利德曼计划通过并购寻求新的增长曲线，推动企业转型。 近日，利德曼（300289.SZ）发布公告称，计划以17.33亿元现金收购北京先声祥瑞生物制品股份有限公 司（下称"先声祥瑞"）70%股份。 本次交易完成后，先声祥瑞将成为利德曼控股子公司，利德曼也将借此切入生物制品领域，构建"生物 制品+体外诊断"双主业模式。 业内认为，通过本次交易，上市公司的业绩将得到提升，财务状况将得到进一步改善，有利于维护上市 公司股东的利益。 标的近年业绩表现稳定 对应高溢价，交易对手方作出了明确的业绩承诺。先声祥瑞2025年、2026年、2027年扣非归母净利润分 别不低于1.66亿元（若剔除2025年mRNA平台费用1035.57万元，则为1.76亿元）、1.86亿元、2.08亿 元，三年累计扣非归母净利润不低于5.58亿元。 先声祥瑞的业务布局是此次收购的核心吸引力之一。作为拥有疫苗生产许可证的企业，其管线覆盖尚未 满足临床需求的人用创新疫苗，其中应用于脑膜炎领域的Xs03项目已提交pre-IND，另有多个创新项目 处于临床前阶段。此外，先声祥瑞在体外诊断试剂的研发、生产和销售领域也具备 ...

Core Points - The company, Lide Man (300289), reported that as of November 10, 2025, the number of shareholders reached 33,374 [1] Summary by Category - **Company Information** - Lide Man has a total of 33,374 shareholders as of the specified date [1]

Group 1 - Lidman shares increased by 5.5% on November 17, reaching 9.59 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 5.36%, resulting in a total market capitalization of 5.217 billion CNY [1] - The stock price of Lidman has risen for six consecutive days, with a cumulative increase of 18.98% during this period [1] - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with the revenue composition being 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, 13.21% from other sources (such as property leasing/management), and 4.78% from biochemical raw materials [1] Group 2 - Among Lidman's top ten circulating shareholders, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 2.0113 million shares, which is 0.37% of the circulating shares [2] - The Medical Device ETF (159883) has generated a floating profit of approximately 1.0056 million CNY today and a total floating profit of 2.9164 million CNY during the six-day increase [2] - The Medical Device ETF was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 9.67% year-to-date, ranking 3702 out of 4216 in its category, and 1.7% over the past year, ranking 3689 out of 3956, while it has incurred a loss of 46.82% since inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 97 days, managing a total fund size of 6.282 billion CNY [3] - During Shu Kefa's tenure, the best fund return was 103.17%, while the worst return was -30.27% [3]

Core Viewpoint - Lidman plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the high-barrier bioproducts industry and transform its business model to include both bioproducts and in vitro diagnostics [1][2] Group 1: Acquisition Details - The acquisition involves cash payment to three entities: Shanghai Baijiahui Investment Management Co., Nanjing Baijiarui Enterprise Management Consulting Partnership, and Hainan Xiansheng Baijiahui Technology Development Co. [1] - After the transaction, Lidman will hold 70% of Xiansheng Xiangrui, consolidating it into its financial statements [1] Group 2: Strategic Rationale - The acquisition allows Lidman to quickly penetrate the bioproducts market, which has high barriers to entry and significant growth potential [2] - Xiansheng Xiangrui is recognized as a "little giant" enterprise in Beijing and holds a vaccine production license, with unique technologies in TB-PPD and BCG-PPD preparation [2] Group 3: Financial Performance - Xiansheng Xiangrui's projected revenues for 2023, 2024, and the first seven months of 2025 are 653 million yuan, 582 million yuan, and 228 million yuan, respectively, with net profits of 210 million yuan, 180 million yuan, and 59.68 million yuan [2] - Lidman expects the acquisition to turn its consolidated net profit positive [2] Group 4: Lidman's Current Situation - Lidman, established in 1997, focuses on in vitro diagnostic reagents and instruments but has faced revenue fluctuations due to increased competition and centralized procurement [3] - For 2024, Lidman's revenue is projected at 370 million yuan, with a net loss of 75.1 million yuan; the first three quarters of this year showed a 10.49% revenue decline [3] - As of the end of Q3, Lidman had cash reserves of 618 million yuan, and the acquisition will result in approximately 1.019 billion yuan of goodwill on its balance sheet [3]

Core Viewpoint - The acquisition of 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. by Lide Man for 1.733 billion yuan raises concerns due to high acquisition premium and the target company's declining performance, leading to potential financial risks for Lide Man [1][2][8] Group 1: Acquisition Details - Lide Man plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, representing a 162.23% premium over the assessed value of the target company [1][2] - The target company has committed to achieving non-net profit targets of 166 million yuan, 186 million yuan, and 208 million yuan for 2025, 2026, and 2027 respectively, totaling 558 million yuan over three years [1][2] - However, the target company reported a significant decline in non-net profit for the first half of 2025, at only 40 million yuan, down 65% year-on-year, raising doubts about meeting these commitments [2][3] Group 2: Financial Implications - The acquisition will generate approximately 1.019 billion yuan in goodwill, which could pose a risk of impairment if the target company’s profitability continues to decline [1][7] - Lide Man's cash reserves are only 618 million yuan, with an additional 281 million yuan in trading financial assets, totaling 899 million yuan, leaving an 800 million yuan shortfall against the acquisition price [5][7] - The acquisition is expected to significantly increase Lide Man's leverage and financial burden, as the cash payment will nearly deplete the company's total assets of 1.809 billion yuan [7][8] Group 3: Target Company Performance - The target company has shown volatile revenue and profit figures, with revenues of 639 million yuan, 653 million yuan, and 582 million yuan for 2022, 2023, and the first half of 2025 respectively, reflecting a 50.34% decline in the first half of 2025 [3][4] - The core product, TB-PPD, accounted for 95.95%, 90.47%, and 77.92% of revenue in 2023, 2024, and the first half of 2025, indicating a high dependency on a single product [3][4] - The target company's revenue from pharmaceutical promotion services in the first half of 2025 was entirely sourced from related party Jiangsu Xiansheng Pharmaceutical, raising concerns about the sustainability and authenticity of this income [4][8]

Group 1 - Duopule plans to reduce its shareholding by no more than 1%, amounting to a maximum of 619,000 shares [1] - Lideman intends to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, focusing on tuberculosis screening and diagnosis [2] - Huahuan Group is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - Dongbai Group clarifies it does not engage in duty-free business, maintaining normal operations [4][5] - Changsheng Bearing's actual controller plans to reduce holdings by up to 1.99%, equating to 5.94 million shares [6][7] - Jidian plans to invest 5.698 billion yuan in the Baicheng Phase II coal power project, a key initiative under the national "14th Five-Year Plan" [9][10] Group 3 - Baoneng New Energy reports completion of land-based works for the expansion of the Lufeng Qiaohai Bay Power Plant [11][12] - Changshu Bank proposes to appoint Lu Dingchang as the new president and chief compliance officer [13][14] - Kangqiang Electronics plans to reduce its shareholding by no more than 1%, totaling up to 3.7526 million shares [14] Group 4 - Jilin Chemical Fiber intends to reduce its holdings by up to 2%, equating to 49.1774 million shares [15][16] - CanSino's inhaled tuberculosis vaccine has commenced Phase I clinical trials in Indonesia [17][18] - ST Dongyi's stock has been suspended for review due to significant price fluctuations [19] Group 5 - ST Yatai plans to reduce its holdings by up to 1.98%, totaling 6.4 million shares [20] - Huaren Pharmaceutical intends to reduce its holdings by up to 3%, equating to 35.4663 million shares [21] - Jianglong Shipbuilding's controlling shareholder plans to reduce holdings by up to 2%, amounting to 7.5534 million shares [22] Group 6 - Borui Pharmaceutical's BGM1812 injection has received approval for clinical trials targeting overweight or obesity [23][24] - ST Zhongzhu announces the transfer of 10.38% of its shares, totaling approximately 403 million yuan [25][26] - Shenzhou Digital plans to establish an employee stock ownership plan with a maximum fundraising of 360 million yuan [27][28] Group 7 - Kaichuang Electric plans to establish a joint research center with Tsinghua University, focusing on embodied intelligence [29] - Daming City intends to acquire 19.43% of Baicaibang for 694 million yuan, specializing in communication solutions [29]